Nippon Shinyaku. 

$31.40
13
+$6.44+25.78% Friday 13:30

統計

當日最高
31.4
當日最低
31.4
52週高點
38.01
52週低點
21
成交量
-
平均成交量
-
市值
0
本益比
10.92
股息殖利率
1.23%
股息
0.39

即將到來

股息

1.23%股息殖利率
Jun 26
$0.39
Dec 25
$0.42
Jun 25
$0.41
Dec 24
$0.43
Jun 24
$0.41
10年成長
9.92%
5年成長
-3.07%
3年成長
-2.65%
1年成長
-6.6%

財報

11Aug預期
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
下一步
0.22
0.53
0.84
1.15
預期EPS
0.7767564
實際EPS
不適用

財務

20.11%利潤率
有盈利
2020
2021
2022
2023
2024
2025
1.35B營收
271.29M淨利

其他人也在關注

此清單是根據在 Stock Events 上追蹤 NPNKF 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Nippon Shinyaku Co., Ltd., founded in Kyoto, Japan, in 1911, operates globally as a developer, manufacturer, and distributor of pharmaceutical products and functional foods. The company is organized into two primary divisions: Pharmaceuticals and Functional Food. Within its Pharmaceutical division, Nippon Shinyaku offers an extensive range of medications to markets across Japan, Switzerland, and other international territories. These therapeutic solutions address diverse medical challenges such as urological disorders, inflammatory and allergic conditions, hematologic malignancies, cardiovascular and metabolic diseases, and gastrointestinal ailments. Key pharmaceutical offerings include Zalutia and Eviprostat for benign prostatic urinary issues; Bladderon for frequent urination; Estracyt for prostate cancer; and Cialis for erectile dysfunction. Its oncology and hematology portfolio further encompasses Vidaza for myelodysplastic syndrome; Cylocide for solid tumors and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva, a humanized anti-CD20 monoclonal antibody; Defiterio for sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. The company also provides Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler for allergic rhinitis; Azunol Gargle liquid, an azulene-based gargling solution; Isobide for oral osmotic diuresis and Meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for the management of cancer and chronic pain. Beyond its existing product lines, Nippon Shinyaku actively invests in the research, development, and commercialization of new treatments within gynecology, otorhinolaryngology, and orthopedics. The Functional Food segment delivers a variety of health-oriented products, including health food ingredients, preservatives, protein preparations, supplements, and a selection of spices and condiments.
Show more...
執行長
Mr. Toru Nakai
員工
2213
國家
日本
ISIN
JP3717600005

上市

0 Comments

分享你的想法

FAQ

Nippon Shinyaku. 今天的股價是多少?
NPNKF 目前價格為 $31.40 USD,過去 24 小時上漲了 +25.78%。在圖表上更密切關注 Nippon Shinyaku. 股價表現。
Nippon Shinyaku. 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Nippon Shinyaku. 的股票以代號 NPNKF 進行交易。
Nippon Shinyaku. 下一次財報日期是什麼時候?
Nippon Shinyaku. 將於 August 11, 2026 公布下一次財報。
Nippon Shinyaku. 上一季度的財報如何?
NPNKF 上一季度的財報為每股 0.36 USD,預估為 0.44 USD,帶來 -16.97% 的驚喜。下一季度的預估財報為每股 不適用 USD。
Nippon Shinyaku. 去年的營收是多少?
Nippon Shinyaku. 去年的營收為 1.35BUSD。
Nippon Shinyaku. 去年的淨利是多少?
NPNKF 去年的淨收益為 271.29MUSD。
Nippon Shinyaku. 會發放股息嗎?
是的,NPNKF 的股息每 半年一次 發放一次。每股最新股息為 0.42 USD。截至今日,股息殖利率(FWD)% 為 1.23%。
Nippon Shinyaku. 有多少名員工?
截至 June 11, 2026,公司共有 2,213 名員工。
Nippon Shinyaku. 位於哪個產業?
Nippon Shinyaku.從事於Health & Wellness產業。
Nippon Shinyaku. 何時完成拆股?
Nippon Shinyaku. 最近沒有進行任何拆股。
Nippon Shinyaku. 的總部在哪裡?
Nippon Shinyaku. 的總部位於 日本 的 Kyoto。